ALS Therapeutic Agent Using Patient-Derived iPS Cell Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for amyotrophic lateral sclerosis (ALS) are ineffective due to the lack of accurate disease models, particularly for sporadic and familial ALS with mutations in the FUS gene or TAR DNA-binding protein 43 kDa (TDP-43) gene, leading to limited progress in treatment development.
Innovation Solution
The use of disease-specific induced pluripotent stem cells (iPS cells) to differentiate into motor neurons, allowing for the development of accurate disease models and the identification of effective therapeutic agents, such as the compound 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one (ropinirole), which demonstrates therapeutic effects on both sporadic and familial ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing disease models (wobbler mice, SOD1 transgenic mice) are used for drug discovery, then research can proceed with available models, but the therapeutic agents selected do not exhibit usefulness in actual ALS patients due to model inaccuracy
Solution Approach 1:
The patent uses patient-derived iPS cells to create in vitro disease models that accurately copy the pathological features of actual ALS patients. Motor neurons differentiated from iPS cells of patients with FUS or TDP-43 mutations reproduce the specific disease mechanisms, providing a faithful copy of the human disease state for drug screening and validation.
2Measurement precision
If iPS cells from ALS patients are used to create accurate disease models, then therapeutic agent selection accuracy improves, but the complexity of cell culture and differentiation processes increases
Solution Approach 1:
The patent performs preliminary differentiation of iPS cells into motor neurons before drug screening, establishing the appropriate cellular context in advance. This preliminary action of differentiating cells to their disease-relevant state ensures that subsequent drug testing occurs in the correct physiological environment, improving both accuracy and efficiency.
Solution Approach 2:
The patent uses iPS cells as an intermediary between patient genetics and drug testing. The iPS cells serve as a mediator that translates patient-specific genetic mutations (FUS or TDP-43) into phenotypic expressions that can be observed and measured in culture, bridging the gap between genotype and drug response assessment.
3Measurement precision
If disease-specific iPS cells are used to differentiate into motor neurons for in vitro disease reproduction, then accurate disease models can be produced, but the time and resources required for cell induction and differentiation increase
Solution Approach 1:
The patent optimizes differentiation parameters including growth factor concentrations, culture conditions, and time points to accelerate motor neuron generation from iPS cells. By carefully controlling parameters such as BMP4, SB431542, and CHIR99021 dosages and timing, the differentiation process is streamlined to achieve motor neuron maturation in the shortest possible time while maintaining disease phenotype accuracy.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
A therapeutic agent for amyotrophic lateral sclerosis including a compound represented by Formula (1) [in Formula (1), R1 each independently represents an alkyl group having 1 to 6 carbon atoms or 4-hydroxyphenethyl group, and n represents an integer of 1 to 3], a pharmaceutically acceptable salt thereof, or a solvate thereof, as an effective ingredient.